OverviewSuggest Edit

Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. It focuses on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases. Its lead product candidate is Lanifibranor that is Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The Company also develops Odiparcil, which is Phase IIa clinical trial for the treatment of mucopolysaccharidosis I, II and VI diseases; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment.

TypePublic
Founded2011
HQDaix, FR
Websiteinventivapharma.com

Latest Updates

Employees (est.) (May 2021)88(+3%)
Share Price (May 2021)€11.9
Cybersecurity ratingAMore

Key People/Management at Inventiva

Frédéric Cren

Frédéric Cren

CO-Founder and CEO, Director
Pierre Broqua

Pierre Broqua

CSO and Co-Founder
Michael Cooreman

Michael Cooreman

Chief Medical Officer
Jean Volatier

Jean Volatier

Chief Financial Officer
Chris Buyse

Chris Buyse

Director
Lucy Lu

Lucy Lu

Director
Show more

Inventiva Office Locations

Inventiva has an office in Daix
Daix, FR (HQ)
50 Rue de Dijon
Show all (1)

Inventiva Financials and Metrics

Inventiva Revenue

Market capitalization (12-May-2021)

459.7m

Closing stock price (12-May-2021)

11.9
Inventiva's current market capitalization is €459.7 m.
Show all financial metrics

Inventiva Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Inventiva Online and Social Media Presence

Embed Graph

Inventiva News and Updates

Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases

Daix (France), May 12, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant…

Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

Daix (France), March 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significan…

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen

 ►     The Company will collaborate with Professor Jérôme Boursier, M.D., Ph.D, a renowned scientist in the field of non-invasive diagnosis of liver lesions in chronic liver diseases

Inventiva to participate at several investor conferences in March 2021

Daix (France), February 24, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with signifi…

Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »

Daix (France), January 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significa…

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Daix (France), January 5, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significa…
Show more

Inventiva Blogs

Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

Daix (France), April 26, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significan…

Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting

Daix (France), March 25, 2021 – Given the current health context, in accordance with the provisions of Order no. 2020-321 of March 25, 2020 adapting the form of meeting and decision-making rules for shareholders meetings and governing bodies of legal entities during the COVID-19 pandemic, as proroga…

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

Daix (France), February 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with signifi…

Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference

Daix (France), January 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significa…

Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology

Daix (France), November 2, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with signific…

Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020

Daix (France), November 2, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with signific…
Show more

Inventiva Frequently Asked Questions

  • When was Inventiva founded?

    Inventiva was founded in 2011.

  • Who are Inventiva key executives?

    Inventiva's key executives are Frédéric Cren, Pierre Broqua and Michael Cooreman.

  • How many employees does Inventiva have?

    Inventiva has 88 employees.

  • Who are Inventiva competitors?

    Competitors of Inventiva include ImmVira, NOXXON Pharma and Plus Therapeutics.

  • Where is Inventiva headquarters?

    Inventiva headquarters is located at 50 Rue de Dijon, Daix.

  • Where are Inventiva offices?

    Inventiva has an office in Daix.

  • How many offices does Inventiva have?

    Inventiva has 1 office.